Pimavanserin 34 mg + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intermittent Explosive Disorder
Conditions
Intermittent Explosive Disorder
Trial Timeline
Aug 1, 2024 → Jan 1, 2028
NCT ID
NCT05895513About Pimavanserin 34 mg + Placebo
Pimavanserin 34 mg + Placebo is a phase 2 stage product being developed by Acadia Pharmaceuticals for Intermittent Explosive Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05895513. Target conditions include Intermittent Explosive Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05895513 | Phase 2 | Recruiting |
Competing Products
12 competing products in Intermittent Explosive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg | AstraZeneca | Approved | 85 |
| LLG783 + Placebo | Novartis | Phase 2 | 52 |
| Azithromycin plus chloroquine + sulfadoxine-pyrimethamine | Pfizer | Phase 3 | 76 |
| ataciguat (HMR1766) + placebo + cilostazol | Sanofi | Phase 2 | 51 |
| Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 | Sanofi | Phase 2 | 51 |
| SL650472, Clopidogrel | Sanofi | Phase 2 | 51 |
| Givosiran | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| Givosiran + 5-probe cocktail | Alnylam Pharmaceuticals | Phase 1 | 30 |
| givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Sapropterin Dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 49 |
| Tetrahydrobiopterin 10 mg/kg + Tetrahydrobiopterin 20 mg/kg + L-Ascorbate + L-Arginine | BioMarin Pharmaceutical | Phase 1 | 30 |
| Placebo + 375 mg CK-2017357 + 500 mg CK-2017357 | Cytokinetics | Phase 2 | 49 |